Suppr超能文献

乳腺原位癌患者在最终手术切缘处局部复发的风险:是否需要再次切除?

Risk of local failure in breast cancer patients with lobular carcinoma in situ at the final surgical margins: is re-excision necessary?

机构信息

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):726-30. doi: 10.1016/j.ijrobp.2013.08.012. Epub 2013 Sep 21.

Abstract

PURPOSE

To compare the outcome of patients with invasive breast cancer both with and without lobular carcinoma in situ (LCIS)-positive/close surgical margins after breast-conserving treatment.

METHODS AND MATERIALS

We retrospectively studied 2358 patients with T1-T2 invasive breast cancer treated with lumpectomy and radiation therapy from January 1980 to December 2009. Median age was 57 years (range, 24-91 years). There were 82 patients (3.5%) with positive/close LCIS margins (<0.2 cm) and 2232 patients (95.7%) with negative margins. A total of 1789 patients (76%) had negative lymph nodes. Patients who received neoadjuvant chemotherapy were excluded. A total of 1783 patients (76%) received adjuvant systemic therapy. Multivariable analysis (MVA) was performed using Cox's proportional hazards model.

RESULTS

The 5-year cumulative incidence of locoregional recurrence (LRR) was 3.2% (95% confidence interval [CI] 2.5%-4.1%) for the 2232 patients with LCIS-negative surgical margins (median follow-up 104 months) and 2.8% (95% CI 0.7%-10.8%) for the 82 patients with LCIS-positive/close surgical margins (median follow-up 90 months). This was not statistically significant (P=.5). On MVA, LCIS-positive margins after the final surgery were not associated with increased risk of LRR (hazard ratio [HR] 3.4, 95% CI 0.5-24.5, P=.2). Statistically significant prognostic variables on Cox's MVA for risk of LRR included systemic therapy (HR 0.5, 95% CI 0.33-0.75, P=.001), number of positive lymph nodes (HR 1.11, 95% CI 1.05-1.18, P=.001), menopausal status (HR 0.96, 95% CI 0.95-0.98, P=.001), and histopathologic grade (grade 3 vs grade 1/2) (HR 2.6, 95% CI 1.4-4.7, P=.003).

CONCLUSION

Our results suggest that the presence of LCIS at the surgical margin after lumpectomy does not increase the risk of LRR or the final outcome. These findings suggest that re-excision or mastectomy in patients with LCIS-positive/close final surgical margins is unnecessary.

摘要

目的

比较保乳治疗后浸润性乳腺癌患者伴或不伴原位癌(LCIS)阳性/切缘接近的手术结局。

方法和材料

我们回顾性研究了 1980 年 1 月至 2009 年 12 月期间接受保乳切除术和放射治疗的 2358 例 T1-T2 浸润性乳腺癌患者。中位年龄为 57 岁(范围 24-91 岁)。82 例(3.5%)患者的 LCIS 切缘阳性/接近(<0.2cm),2232 例(95.7%)患者切缘阴性。共有 1789 例(76%)患者淋巴结阴性。排除接受新辅助化疗的患者。共有 1783 例(76%)患者接受辅助全身治疗。采用 Cox 比例风险模型进行多变量分析(MVA)。

结果

2232 例 LCIS 切缘阴性患者(中位随访 104 个月)的 5 年局部区域复发(LRR)累积发生率为 3.2%(95%CI 2.5%-4.1%),82 例 LCIS 切缘阳性/接近患者为 2.8%(95%CI 0.7%-10.8%),无统计学意义(P=.5)。MVA 显示,最终手术后 LCIS 阳性切缘与 LRR 风险增加无关(风险比 [HR] 3.4,95%CI 0.5-24.5,P=.2)。Cox MVA 对 LRR 风险的显著预后变量包括系统治疗(HR 0.5,95%CI 0.33-0.75,P=.001)、阳性淋巴结数量(HR 1.11,95%CI 1.05-1.18,P=.001)、绝经状态(HR 0.96,95%CI 0.95-0.98,P=.001)和组织病理学分级(3 级 vs 1/2 级)(HR 2.6,95%CI 1.4-4.7,P=.003)。

结论

我们的结果表明,保乳切除术后 LCIS 位于切缘并不增加 LRR 或最终结局的风险。这些发现表明,LCIS 阳性/切缘接近的患者不需要再次切除或乳房切除术。

相似文献

1
Risk of local failure in breast cancer patients with lobular carcinoma in situ at the final surgical margins: is re-excision necessary?
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):726-30. doi: 10.1016/j.ijrobp.2013.08.012. Epub 2013 Sep 21.
6
The safety of multiple re-excisions after lumpectomy for breast cancer.
Ann Surg Oncol. 2011 Dec;18(13):3797-801. doi: 10.1245/s10434-011-1802-4. Epub 2011 Jun 1.
7
Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.
Cancer. 1996 Oct 1;78(7):1403-16. doi: 10.1002/(SICI)1097-0142(19961001)78:7<1403::AID-CNCR6>3.0.CO;2-L.
10
Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence?
Ann Surg Oncol. 2023 Oct;30(10):6061-6069. doi: 10.1245/s10434-023-13899-1. Epub 2023 Jul 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验